Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-1965
- Development stage
- Phase 2
- Lead developer
- Alyssum Therapeutics
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AT-1965 is a liposomal formulation of a small molecule inhibitor targeting cap-specific mRNA (nucleoside-2-O-) methyltransferase 2 (CMTR2, also known as MTR2 or FTSJD1). It is designed to have immunomodulating and antineoplastic activities. The drug acts as a B-cell stimulant and is being developed for the treatment of advanced, refractory, or recurrent solid tumors, including metastatic triple-negative breast cancer. Its mechanism involves inhibition of CMTR2, which may modulate immune responses and exert anti-tumor effects. The drug is administered intravenously in a liposomal form to enhance delivery and reduce toxicity. Development has been led by Akamara Therapeutics with clinical development by Alyssum Therapeutics[1][2][4][8].
- Other names
- liposomal CMTR2 inhibitor AT-1965
02
Targets
RNMT (RNA guanine-7 methyltransferase)CMTR2 (Cap-specific mRNA (nucleoside-2-O-) methyltransferase 2)
Beyond the preview
Go deeper on AT-1965.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-1965.